Table of Contents

company-logo

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RedHill Biopharma Dividend Announcement

• RedHill Biopharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on RedHill Biopharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

RedHill Biopharma Dividend History

RedHill Biopharma Dividend Yield

RedHill Biopharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing RedHill Biopharma stock? Use our calculator to estimate your expected dividend yield:

RedHill Biopharma Financial Ratios

P/E ratio2.11
PEG ratio-0.04
P/B ratio24.42
ROE-103.24%
Payout ratio0.00%
Current ratio0.84
Quick ratio0.61
Cash Ratio0.29

RedHill Biopharma Dividend FAQ

Does RedHill Biopharma stock pay dividends?
RedHill Biopharma does not currently pay dividends to its shareholders.
Has RedHill Biopharma ever paid a dividend?
No, RedHill Biopharma has no a history of paying dividends to its shareholders. RedHill Biopharma is not known for its dividend payments.
Why doesn't RedHill Biopharma pay dividends?
There are several potential reasons why RedHill Biopharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will RedHill Biopharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While RedHill Biopharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is RedHill Biopharma a dividend aristocrat?
RedHill Biopharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is RedHill Biopharma a dividend king?
RedHill Biopharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is RedHill Biopharma a dividend stock?
No, RedHill Biopharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy RedHill Biopharma stocks?
To buy RedHill Biopharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy RedHill Biopharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.